A hospital-based matched case-control study to identify clinical outcome and risk factors associated with carbapenem-resistant Klebsiella pneumoniae infection

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Correa, Luci ^a,b   Martino, Marines Dalla Valle ^a   Siqueira, Itacy ^a   Pasternak, Jacyr ^a   Gales, Ana Cristina ^b   Silva, Claudia Vallone ^a   Camargo, Thiago Zinsly Sampaio ^a   Scherer, Patricia Faria ^a   Marra, Alexandre Rodrigues ^a  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Carbapenem resistant Klebsiella; Healthcare associated infections; Klebsiella infections microbiology; Klebsiella infections mortality; Klebsiella pneumoniae

Indexed keywords

CARBAPENEM; OUTER MEMBRANE PROTEIN; PROTEIN OMPK35; PROTEIN OMPK36; UNCLASSIFIED DRUG;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; ENZYME ACTIVITY; ENZYME SYNTHESIS; FEMALE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; KLEBSIELLA PNEUMONIAE INFECTION; MALE; MORTALITY; OUTCOME ASSESSMENT; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PULSED FIELD GEL ELECTROPHORESIS; RISK ASSESSMENT; RISK FACTOR; SPECTROPHOTOMETRY;

ANTI-BACTERIAL AGENTS; CARBAPENEMS; CASE-CONTROL STUDIES; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; HOSPITAL MORTALITY; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; RISK FACTORS;

EID: 84873511315     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-80     Document Type: Article

References (42)

1. Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med 2010, 362:1804-1813. 10.1056/NEJMra0904124, 3107499, 20463340.
2. Talbot GH, Bradley J, Edwards JE, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006, 42:657-658. 10.1086/499819, 16447111.
3. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, Bartlett JG, Edwards JE, Infectious Diseases Society of America The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:155-164. 10.1086/524891, 18171244, Infectious Diseases Society of America.
4. Lockhart SR, Abramson MA, Beekmann SE, Gallagher G, Riedel S, Diekema DJ, Quinn JP, Doern GV. Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol 2007, 45:3352-3359. 10.1128/JCM.01284-07, 2045364, 17715376.
5. Hawkey PM. Prevalence and clonality of extended-spectrum beta-lactamases in Asia. Clin Microbiol Infect 2008, 14(Suppl 1):159-165.
6. Villegas MV, Kattan JN, Quinteros MG, Casellas JM. Prevalence of extended-spectrum beta-lactamases in South America. Clin Microbiol Infect 2008, 14(Suppl 1):154-158.
7. Bush K. Extended-spectrum beta-lactamases in North America, 1987-2006. Clin Microbiol Infect 2008, 14(Suppl 1):134-143.
8. Falagas ME, Karageorgopoulos DE. Extended-spectrum beta-lactamases-producing organisms. J Hosp Infect 2009, 73:345-354. 10.1016/j.jhin.2009.02.021, 19596491.
9. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009, 9:228-236. 10.1016/S1473-3099(09)70054-4, 19324295.
10. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK, National Healthcare Safety Network Team Participating National Healthcare Safety Network Facilities NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemio 2008, 29:996-1011. National Healthcare Safety Network Team Participating National Healthcare Safety Network Facilities.
11. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008, 29:1099-1106. 10.1086/592412, 18973455.
12. Souli M, Galani I, Antoniadou A, Papadomichelakis E, Poulakou G, Panagea T, Vourli S, Zerva L, Armaganidis A, Kanellakopoulou K, Giamarellou H. An outbreak of infection due to beta-lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis 2010, 50:364-373. 10.1086/649865, 20041768.
13. Marchain D, Navon-Venezia S, Schwaber MJ, Carmeli Y. Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob Agents Chemother 2008, 52:1413-1418. 10.1128/AAC.01103-07, 2292520, 18227191.
14. Bratu S, Landman D, Haag R, Recco R, Eramo A, Alam M, Quale J. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City. A new treat to our antibiotic armamentarium. Arch Intern Med 2005, 165:1430-1435. 10.1001/archinte.165.12.1430, 15983294.
15. Falagas ME, Rafailidis PI, Kofteridis D, Virtzili S, Chelvatzoglou FC, Papaioannou V, Maraki S, Samonis G, Michalopoulos A. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother 2007, 60:1124-1130. 10.1093/jac/dkm356, 17884829.
16. Nguyen M, Eschenauer GA, Bryan M, O'Neil K, Furuya EY, Della-Latta P, Kubin CJ. Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. Diagn Microbiol Infect Dis 2010, 67:180-184. 10.1016/j.diagmicrobio.2010.02.001, 20356699.
17. Munoz-Price LS, Quinn JP. The spread of Klebsiella pneumoniae carbapenemases: a tale of strains, plasmids, and transposons. Clin Infect Dis 2009, 49:1739-1741. 10.1086/648078, 19886796.
18. Monteiro J, Santos AF, Asensi MD, Peirano G, Gales AC. First report of KPC-2 producing Klebsiella pneumoniae strains in Brazil. Antimicrob Agents Chemother 2009, 53:333-334. 10.1128/AAC.00736-08, 2612176, 19015350.
19. Peirano G, Seki LM, Val Passos VL, Pinto MCFG, Guerra LR, Asensi MD. Carbapenem-hydrolysing β-lactamase KPC-2 in Klebsiella pneumoniae isolated in Rio de Janeiro, Brazi. J Antimicrob Chemother 2009, 63:265-268.
20. Pavez M, Mamizuka EM, Lincopan N. Early dissemination of KPC-2-producing Klebsiella pneumoniae strains in Brazil. Antimicrob Agents Chemother 2009, 53:2702. 10.1128/AAC.00089-09, 2687248, 19332672.
21. Hussein K, Sprecher H, Mashiach T, Oren I, Kassis I, Filkenstein R. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol 2009, 30:666-671. 10.1086/598244, 19496647.
22. Centers for Diseases Control and Prevention Guidance for control of infections with carbapenem-resistant or carbapenemase-produzing Enterobacteriaceae in acute care facilities. MMWR 2009, 58:256-260. Centers for Diseases Control and Prevention.
23. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008, 36:309-332. 10.1016/j.ajic.2008.03.002, 18538699.
24. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; 19th informational supplement. CLSI document M100-S19 2009, Wayne, PA: Clinical and Laboratory StandardsInstitute, Clinical and Laboratory Standards Institute.
25. Charlson ME, Sax FL, MacKenzie CR, Fields SD, Braham RL, Douglas RGJ. Assessing illness severity: does clinical judgment work?. J Chronic Dis 1986, 39:439-452. 10.1016/0021-9681(86)90111-6, 3086355.
26. McCabe WR, Jackson GG. Gram-negative bacteremia II: clinical, laboratory, and therapeutic observations. Arch Intern Med 1962, 110:856-864.
27. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829. 10.1097/00003246-198510000-00009, 3928249.
28. Vincent JL, De Mendonça A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med 1998, 26:1793-1800. 10.1097/00003246-199811000-00016, 9824069.
29. Marra AR, Wey SB, Castelo A, Gales AC, Cal RG, Filho JR, Edmond MB, Pereira CA. Nosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extended-spectrum beta-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence. BMC Infect Dis 2006, 6:24. 10.1186/1471-2334-6-24, 1382232, 16478537.
30. Byl B, Clevenbergh P, Jacobs F, Struelens MJ, Zech F, Kentos A, Thys JP. Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia. Clin Infect Dis 1999, 29:60-66. 10.1086/520182, 10433566.
31. Paterson DL, Ko W-C, Gotteberg A, Casellas JM, Mulazimoglu L, Klugman KP, Bonomo R, Rice LB, McCormack JG, Yu VL. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001, 39:2206-2212. 10.1128/JCM.39.6.2206-2212.2001, 88112, 11376058.
32. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20:864-874. 10.1097/00003246-199206000-00025, 1597042, American College of Chest Physicians/Society of Critical Care Medicine.
33. Picão RC, Poirel L, Gales AC, Nordmann P. Diversity of β-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolates causing bloodstream infections in Brazil. Antimicrob Agents Chemother 2009, 53:3908-3913. 10.1128/AAC.00453-09, 2737865, 19596871.
34. Mendes RE, Kiyota KA, Monteiro J, Castanheira M, Andrade SS, Gales AC, Pignatari AC, Tufik S. Rapid detection and identification of metallo-beta-lactamase-encoding genes by multiplex real time PCR assay and melt curve analysis. J Clin Microbiol 2007, 45:544-547. 10.1128/JCM.01728-06, 1829038, 17093019.
35. Poirel L, Heritier C, Tolün V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004, 48:15-22. 10.1128/AAC.48.1.15-22.2004, 310167, 14693513.
36. Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S, Amyes SG, Livermore DM. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents 2006, 27:351-353. 10.1016/j.ijantimicag.2006.01.004, 16564159.
37. Kaczmarek FM, Dib-Hajj F, Shang W, Gootz TD. High-level carbapenem resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of blaACT-1 beta-lactamase production, porin OmpK35/36 insertional inactivation, and down-regulation of the phosphate transport porin phoe. Antimicrob Agents Chemother 2006, 50(10):3396-3406. 10.1128/AAC.00285-06, 1610099, 17005822.
38. Tenover FC, Kalsi RK, Williams PP, Carey RB, Stocker S, Lonsway D, Rasheed JK, Biddle JW, McGowan JE, Hannat B. Carbapenem resistant in Klebsiella pneumoniae not detected by automated susceptibility testing. Emerg Infect Dis 2006, 12:1209-1213. 10.3201/eid1708.060291, 3291231, 16965699.
39. Carvalhaes CG, Picão RC, Nicoletti AG, Xavier DE, Gales AC. Cloverleaf test (modified Hodge test) for detecting carbapenemase production in Klebsiella pneumoniae: be aware of false positive results. J Antimicrob Chemother 2010, 65:249-251. 10.1093/jac/dkp431, 19996141.
40. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995, 33:2233-2239. 228385, 7494007.
41. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemio 2009, 30:1180-1185.
42. Borer A, Saidel-Odes L, Riesenberg K, Eskira S, Peled N, Nativ R, Schlaeffer F, Sherf M. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol 2009, 30:972-976. 10.1086/605922, 19712030.